White Papers

  1. 2026 Clinical Trials: Strong Headwinds, Winds Of Change 6/11/2026

    Are your Phase I–III/IV clinical studies prepared for today's regulatory landscape? Learn how leading organizations are addressing compliance, transparency, and data ownership risks.

  2. How Remote Pharmacy Monitoring Improves Trial Compliance 6/10/2026

    Explore how leading IDS pharmacies are using remote monitoring workflows and digital accountability systems to improve accuracy, reduce site burden, and maintain audit readiness.

  3. Demonstrating IDS Value With Time-Based Metrics 6/10/2026

    Explore how leading IDS pharmacies are using remote monitoring workflows and digital accountability systems to improve accuracy, reduce site burden, and maintain audit readiness.

  4. Meeting The FDA's New Real-World Evidence Standards 5/27/2026

    FDA guidance is reshaping RWE strategy. Sponsors that build interoperable, audit-ready RWD infrastructure now will be best positioned for faster, defensible submissions.

  5. The eCOA Iceberg 5/27/2026

    Understand the true cost of eCOA deployment, beyond software licenses, to reduce protocol risk, avoid operational bottlenecks, and protect study timelines and data quality.

  6. Navigating The Challenges Of Large, International Phase III Breast Cancer Trials 5/27/2026

    In the competitive landscape of breast cancer research, aligning biomarker testing, regulatory pathways, and regional operations from day one creates a path to faster enrollment and stronger outcomes.

  7. De-Risking The Neurology IND: Lessons From Early FDA Engagement 5/27/2026

    Learn how early FDA alignment can help your neurology program move forward with greater clarity, confidence, and regulatory readiness.

  8. Faster Starts, Stronger Finish: Operational Excellence In NSCLC 5/22/2026

    In NSCLC trials, data‑driven site selection, streamlined protocols, efficient screening strategies, and proactive engagement can accelerate enrollment and improve trial efficiency across regions.

  9. How Adaptive Design Accelerates Early‑Phase NSCLC Development 5/22/2026

    Adaptive trial designs and an adaptive mindset enable non-small cell lung cancer (NSCLC) sponsors to optimize dose, respond to evolving expectations, and accelerate early‑phase development.

  10. Rethinking Trial Access Through Trust-Driven Design And Local Collaboration 5/19/2026

    Locally embedded research models help sponsors reach underserved populations while reducing burden on patients and health systems alike.